ZT55
Based on 1 Customer Validation
ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC50 value of 0.031 μM. ZT55 inhibits the proliferation of JAK2V617F-expressing HEL cell lines and induces apoptosis and cycle arrest. ZT-55 also effectively inhibits the growth of HEL xenograft tumours in a mice model. ZT-55 can be used in studies of myeloproliferative neoplasms, polycythemia vera and primary thrombocythemia.
For research use only. We do not sell to patients.
- Purity: 99.51%
- CAS No.: 2138488-38-5
- Formula: C17H16N2O3
- Molecular Weight:296.32
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
JAK/STAT Compound Library
HY-L008
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Orally Active Compound Library
HY-L061
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Obesity Compound Library
HY-L087
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Autoimmune Disease Compound Library
HY-L156
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Posttranslational Modification Library
HY-L226
Biological Activity
|
JAK2 0.031 μM (IC50) |
ZT55 (0-100 μM; 48 h) inhibits the proliferation of JAK2V617F (+) HEL cells in a concentration-dependent manner (IC50=18.05 μM)[1].
ZT55 (12.5, 25, 50 μM; 24, 48, 72 h) inhibits the cell viability and induces apoptosis of HEL cells in a concentration- and time-dependent manner[1].
ZT55 (12.5, 25, 50 μM; 24 h) arrests HEL cells in the G2/M phase in a concentration-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEL cells (JAK2V617F(+))
-
Concentration:0-100 μM
-
Incubation Time:48 h
-
Result:Significantly inhibited proliferation in a concentration-dependent manner (IC50=18.05 μM).
-
Cell Line:HEL cells
-
Concentration:12.5, 25, 50 μM
-
Incubation Time:24, 48, 72 h
-
Result:Inhibited viability of HEL cells in a concentration- and time-dependent manner.
-
Cell Line:HEL cells (JAK2V617F(+))
-
Concentration:0-100 μM
-
Incubation Time:24, 48, 72 h
-
Result:Induced cell apoptosis in a concentration- and time-dependent manner.
-
Cell Line:HEL cells (JAK2V617F(+))
-
Concentration:0-100 μM
-
Incubation Time:24, 48, 72 h
-
Result:Significantly increased the number of HEL cells in the G2/M phase in a concentration-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female, athymic BALB/c nude mice (6 to 8-week-old; JAK2V617F xenograft model)[1].
-
Dosage:100 mg/kg
-
Administration:Oral administration; once a day for 2 weeks
-
Result:Induced marked reductions in tumor volume.
Chemical Information
-
CAS No. 2138488-38-5
-
Appearance Solid
-
Molecular Weight 296.32
-
Formula C17H16N2O3
-
Color White to off-white
-
SMILES
O=C(NC1=CC=CC=C1OC)CC2=CN(O)C3=C2C=CC=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (337.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3747 mL | 16.8736 mL | 33.7473 mL | 84.3682 mL |
| 5 mM | 0.6749 mL | 3.3747 mL | 6.7495 mL | 16.8736 mL | |
| 10 mM | 0.3375 mL | 1.6874 mL | 3.3747 mL | 8.4368 mL | |
| 15 mM | 0.2250 mL | 1.1249 mL | 2.2498 mL | 5.6245 mL | |
| 20 mM | 0.1687 mL | 0.8437 mL | 1.6874 mL | 4.2184 mL | |
| 25 mM | 0.1350 mL | 0.6749 mL | 1.3499 mL | 3.3747 mL | |
| 30 mM | 0.1125 mL | 0.5625 mL | 1.1249 mL | 2.8123 mL | |
| 40 mM | 0.0844 mL | 0.4218 mL | 0.8437 mL | 2.1092 mL | |
| 50 mM | 0.0675 mL | 0.3375 mL | 0.6749 mL | 1.6874 mL | |
| 60 mM | 0.0562 mL | 0.2812 mL | 0.5625 mL | 1.4061 mL | |
| 80 mM | 0.0422 mL | 0.2109 mL | 0.4218 mL | 1.0546 mL | |
| 100 mM | 0.0337 mL | 0.1687 mL | 0.3375 mL | 0.8437 mL |
Powered by Bioz